These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 9931308)

  • 1. A transforming mutation enhances the activity of the c-Kit soluble tyrosine kinase domain.
    Lam LP; Chow RY; Berger SA
    Biochem J; 1999 Feb; 338 ( Pt 1)(Pt 1):131-8. PubMed ID: 9931308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant.
    Shivakrupa R; Bernstein A; Watring N; Linnekin D
    Cancer Res; 2003 Aug; 63(15):4412-9. PubMed ID: 12907613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor.
    Roskoski R
    Biochem Biophys Res Commun; 2005 Nov; 337(1):1-13. PubMed ID: 16129412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transforming and differentiation-inducing potential of constitutively activated c-kit mutant genes in the IC-2 murine interleukin-3-dependent mast cell line.
    Hashimoto K; Tsujimura T; Moriyama Y; Yamatodani A; Kimura M; Tohya K; Morimoto M; Kitayama H; Kanakura Y; Kitamura Y
    Am J Pathol; 1996 Jan; 148(1):189-200. PubMed ID: 8546206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fyn kinase acts upstream of Shp2 and p38 mitogen-activated protein kinase to promote chemotaxis of mast cells towards stem cell factor.
    Samayawardhena LA; Hu J; Stein PL; Craig AW
    Cell Signal; 2006 Sep; 18(9):1447-54. PubMed ID: 16442778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591.
    Vempati S; Reindl C; Wolf U; Kern R; Petropoulos K; Naidu VM; Buske C; Hiddemann W; Kohl TM; Spiekermann K
    Clin Cancer Res; 2008 Jul; 14(14):4437-45. PubMed ID: 18628457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells.
    Wai DH; Knezevich SR; Lucas T; Jansen B; Kay RJ; Sorensen PH
    Oncogene; 2000 Feb; 19(7):906-15. PubMed ID: 10702799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.
    Roskoski R
    Biochem Biophys Res Commun; 2005 Dec; 338(3):1307-15. PubMed ID: 16226710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signal transduction by several KIT juxtamembrane domain mutations.
    Casteran N; De Sepulveda P; Beslu N; Aoubala M; Letard S; Lecocq E; Rottapel R; Dubreuil P
    Oncogene; 2003 Jul; 22(30):4710-22. PubMed ID: 12879016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of constitutive activation of c-kit receptor tyrosine kinase.
    Tsujimura T; Kanakura Y; Kitamura Y
    Leukemia; 1997 Apr; 11 Suppl 3():396-8. PubMed ID: 9209403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
    Raafat A; Zoltan-Jones A; Strizzi L; Bargo S; Kimura K; Salomon D; Callahan R
    Oncogene; 2007 Feb; 26(5):662-72. PubMed ID: 16878155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms.
    Zermati Y; De Sepulveda P; Féger F; Létard S; Kersual J; Castéran N; Gorochov G; Dy M; Ribadeau Dumas A; Dorgham K; Parizot C; Bieche Y; Vidaud M; Lortholary O; Arock M; Hermine O; Dubreuil P
    Oncogene; 2003 Feb; 22(5):660-4. PubMed ID: 12569358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
    Horn S; Bergholz U; Jücker M; McCubrey JA; Trümper L; Stocking C; Bäsecke J
    Oncogene; 2008 Jul; 27(29):4096-106. PubMed ID: 18317450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of activation of human c-KIT kinase by internal tandem duplications of the juxtamembrane domain and point mutations at aspartic acid 816.
    Kim SY; Kang JJ; Lee HH; Kang JJ; Kim B; Kim CG; Park TK; Kang H
    Biochem Biophys Res Commun; 2011 Jul; 410(2):224-8. PubMed ID: 21640708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.
    Zhu MJ; Ou WB; Fletcher CD; Cohen PS; Demetri GD; Fletcher JA
    Oncogene; 2007 Sep; 26(44):6386-95. PubMed ID: 17452978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression, purification, and characterization of Bacneu. A soluble protein tyrosine kinase domain encoded by the neu-oncogene.
    Myers JN; LeVea CM; Smith JE; Kallen RG; Tung L; Greene MI
    Receptor; 1992; 2(1):1-16. PubMed ID: 1362129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein.
    Weiner DB; Kokai Y; Wada T; Cohen JA; Williams WV; Greene MI
    Oncogene; 1989 Oct; 4(10):1175-83. PubMed ID: 2571965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation.
    Tsujimura T; Furitsu T; Morimoto M; Isozaki K; Nomura S; Matsuzawa Y; Kitamura Y; Kanakura Y
    Blood; 1994 May; 83(9):2619-26. PubMed ID: 7513208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modifications of tumor histology by point mutations in the v-fps oncogene: possible role of extracellular matrix.
    Auersperg N; Pawson T; Worth A; Weinmaster G
    Cancer Res; 1987 Dec; 47(23):6341-8. PubMed ID: 3315185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells.
    Piao X; Bernstein A
    Blood; 1996 Apr; 87(8):3117-23. PubMed ID: 8605325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.